Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Breast cancer highlights from ASCO 2019

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.06.19
Views: 3536

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Dr Matteo Lambertini speaks with ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the conference highlights in breast cancer research.

He first discusses results from two studies in the metastatic HER2-positive setting, the SOPHIA trial and the NALA trial, before going on to discuss two studies in hormone receptor positive metastatic breast cancer, the MONALEESA-7 trial and a Korean trial investigating whether it's better to start with chemotherapy or endocrine therapy.

Dr Lambertini then reports findings from an international, retrospective study that he presented on the safety of pregnancy following breast cancer in patients with a BRCA mutation.

He concludes by discussing the GeparOLA and the GIM4 trials.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation